Nasdaq
$44.78▲ 1.73%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.56BShares out 34.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
32- 4d agoAfter-hours26.10.21 05:058-KKey event#●●●#●●●
First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of common stock on October 19, 2026. Under the signed registration rights agreement, the company is required to file a resale registration statement with the SEC within 30 days, subject to liquidated damages payable in cash if filing or effectiveness deadlines are missed.…more
$44.78+1.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 05:288-KKey event
First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics has entered into a definitive agreement to raise approximately $200 million in gross proceeds through a private placement of 6,106,870 shares of common stock at $32.75 per share. The company intends to use the proceeds for general corporate purposes, including the clinical development of its CD122 antagonist, ANB033.…more
$44.78+1.73%vs prev closeView filingShare - 10.13Pre-market26.10.13 21:328-KKey event
First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics announced positive topline results from the Phase 1b trial of ANB033 for celiac disease, demonstrating statistically significant efficacy in preventing intestinal damage and symptoms. The company plans to advance ANB033 into late-stage clinical development in 2027.…more
$44.78+1.73%vs prev closeView filingShare
31 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 21:02Bullish#●●●#●●●#●●●
First Tracks Biotherapeutics Announces $200M Private Placement
First Tracks Biotherapeutics has entered into a securities purchase agreement to raise approximately $200 million through a private placement of common stock to institutional investors. The company plans to utilize the proceeds for general corporate purposes, including the clinical development of its CD122 antagonist, ANB033.…more
$44.78+1.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.12Pre-market26.10.12 21:23
●●●●●●●● ●●●●● ●●●●●●
First Tracks Biotherapeutics reported that its celiac disease candidate ANB033 met all primary efficacy endpoints and demonstrated a favorable safety profile in a Phase 1b trial. Following these positive results, the company is now preparing for late-stage clinical development.…more
$44.78+1.73%vs prev closeShareBenzinga - 10.12Pre-market26.10.12 20:00
●●●●●●●● ●●●●● ●●●●●●
First Tracks Biotherapeutics announced that its ANB033 treatment demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms in a Phase 1b trial. While the initial data is positive, the company must still successfully navigate late-stage clinical trials to reach commercialization.…more
$44.78+1.73%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report